These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 38506759)

  • 1. The Effect of Bimatoprost Implant on Glaucoma Patients: An Observational Study.
    Choi EY; Johnson NA; Stinnett S; Rosdahl J; Moya F; Herndon LW
    J Glaucoma; 2024 Jun; 33(6):431-436. PubMed ID: 38506759
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase 3, Randomized, 20-Month Study of the Efficacy and Safety of Bimatoprost Implant in Patients with Open-Angle Glaucoma and Ocular Hypertension (ARTEMIS 2).
    Bacharach J; Tatham A; Ferguson G; Belalcázar S; Thieme H; Goodkin ML; Chen MY; Guo Q; Liu J; Robinson MR; Bejanian M; Wirta DL;
    Drugs; 2021 Nov; 81(17):2017-2033. PubMed ID: 34724172
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase 3, Randomized, 20-Month Study of Bimatoprost Implant in Open-Angle Glaucoma and Ocular Hypertension (ARTEMIS 1).
    Medeiros FA; Walters TR; Kolko M; Coote M; Bejanian M; Goodkin ML; Guo Q; Zhang J; Robinson MR; Weinreb RN;
    Ophthalmology; 2020 Dec; 127(12):1627-1641. PubMed ID: 32544560
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 24-Month Phase I/II Clinical Trial of Bimatoprost Sustained-Release Implant (Bimatoprost SR) in Glaucoma Patients.
    Craven ER; Walters T; Christie WC; Day DG; Lewis RA; Goodkin ML; Chen M; Wangsadipura V; Robinson MR; Bejanian M;
    Drugs; 2020 Feb; 80(2):167-179. PubMed ID: 31884564
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of Topical Bimatoprost 0.01% and Timolol 0.5% on Circadian IOP, Blood Pressure and Perfusion Pressure in Patients with Glaucoma or Ocular Hypertension: A Randomized, Double Masked, Placebo-Controlled Clinical Trial.
    Oddone F; Rossetti L; Tanga L; Berardo F; Ferrazza M; Michelessi M; Roberti G; Manni G; Centofanti M
    PLoS One; 2015; 10(10):e0140601. PubMed ID: 26484767
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bimatoprost Sustained-Release Implants for Glaucoma Therapy: 6-Month Results From a Phase I/II Clinical Trial.
    Lewis RA; Christie WC; Day DG; Craven ER; Walters T; Bejanian M; Lee SS; Goodkin ML; Zhang J; Whitcup SM; Robinson MR;
    Am J Ophthalmol; 2017 Mar; 175():137-147. PubMed ID: 28012819
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Short-Term Outcomes of Bimatoprost Sustained-Release Intracameral Implant in Glaucoma.
    Wong MK; Bowers ME; Ventimiglia J; Niknam RM; Moster MR; Pro MJ; Dale E; Kolomeyer NN; Lee D; Zheng CX
    J Glaucoma; 2023 Sep; 32(9):738-743. PubMed ID: 37523637
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Six-Month Intraocular Pressure Reduction with a Topical Bimatoprost Ocular Insert: Results of a Phase II Randomized Controlled Study.
    Brandt JD; Sall K; DuBiner H; Benza R; Alster Y; Walker G; Semba CP;
    Ophthalmology; 2016 Aug; 123(8):1685-1694. PubMed ID: 27157843
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Flare-up rates with bimatoprost therapy in uveitic glaucoma.
    Fortuna E; Cervantes-Castañeda RA; Bhat P; Doctor P; Foster CS
    Am J Ophthalmol; 2008 Dec; 146(6):876-82. PubMed ID: 19027422
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fixed-combination Bimatoprost/Brimonidine/Timolol in Glaucoma: A Randomized, Masked, Controlled, Phase III Study Conducted in Brazil
    Belfort R; Paula JS; Lopes Silva MJ; Della Paolera M; Kim T; Chen MY; Goodkin ML
    Clin Ther; 2020 Feb; 42(2):263-275. PubMed ID: 32089329
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A 3-month randomized controlled trial of bimatoprost (LUMIGAN) versus combined timolol and dorzolamide (Cosopt) in patients with glaucoma or ocular hypertension.
    Coleman AL; Lerner F; Bernstein P; Whitcup SM
    Ophthalmology; 2003 Dec; 110(12):2362-8. PubMed ID: 14644719
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Late-day intraocular pressure-lowering efficacy and tolerability of travoprost 0.004% versus bimatoprost 0.01% in patients with open-angle glaucoma or ocular hypertension: a randomized trial.
    DuBiner HB; Hubatsch DA
    BMC Ophthalmol; 2014 Nov; 14():151. PubMed ID: 25432143
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of the Ahmed S2 glaucoma valve compared with the Baerveldt 250-mm2 glaucoma implant.
    Goulet RJ; Phan AD; Cantor LB; WuDunn D
    Ophthalmology; 2008 Jul; 115(7):1141-7. PubMed ID: 18164068
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and tolerability of fixed-combination bimatoprost/timolol versus fixed-combination dorzolamide/brimonidine/timolol in patients with primary open-angle glaucoma or ocular hypertension: a multicenter, prospective, crossover study.
    García-López A; Paczka JA; Jiménez-Román J; Hartleben C
    BMC Ophthalmol; 2014 Dec; 14():161. PubMed ID: 25527295
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of bimatoprost on patients with primary open-angle glaucoma or ocular hypertension who are nonresponders to latanoprost.
    Gandolfi SA; Cimino L
    Ophthalmology; 2003 Mar; 110(3):609-14. PubMed ID: 12623831
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dose-Response of Intracameral Bimatoprost Sustained-Release Implant and Topical Bimatoprost in Lowering Intraocular Pressure.
    Lee SS; Dibas M; Almazan A; Robinson MR
    J Ocul Pharmacol Ther; 2019 Apr; 35(3):138-144. PubMed ID: 30698494
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A six-month randomized clinical trial comparing the intraocular pressure-lowering efficacy of bimatoprost and latanoprost in patients with ocular hypertension or glaucoma.
    Noecker RS; Dirks MS; Choplin NT; Bernstein P; Batoosingh AL; Whitcup SM;
    Am J Ophthalmol; 2003 Jan; 135(1):55-63. PubMed ID: 12504698
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and Safety of the Travoprost Intraocular Implant in Reducing Topical IOP-Lowering Medication Burden in Patients with Open-Angle Glaucoma or Ocular Hypertension.
    Berdahl JP; Sarkisian SR; Ang RE; Doan LV; Kothe AC; Usner DW; Katz LJ; Navratil T;
    Drugs; 2024 Jan; 84(1):83-97. PubMed ID: 38060092
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of Intraocular Pressure, Usage of Topical Steroids, Need for Intraocular Pressure Lowering Drops, and Incidence of Glaucoma Surgery Up to 2 Years After Penetrating Keratoplasty and Endothelial Keratoplasty.
    Vu PQ; Aggarwal S; Lu Y; Xie K; Wade M; Bhatt A
    J Glaucoma; 2020 Dec; 29(12):1120-1125. PubMed ID: 32826764
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Single Administration of Bimatoprost Implant: Effects on 24-Hour Intraocular Pressure and 1-Year Outcomes.
    Weinreb RN; Christie WC; Medeiros FA; Craven ER; Kim K; Nguyen A; Bejanian M; Wirta DL
    Ophthalmol Glaucoma; 2023; 6(6):599-608. PubMed ID: 37343625
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.